Search Results - "Gerrie, A."

VP12.02: Conservative management of presumed fetal anemia secondary to maternal chemotherapy for acute myeloid leukemia by Nowik, C., Gerrie, A., Wong, J.

Get full text

Observation as the initial management strategy in patients with mantle cell lymphoma by Abrisqueta, P., Scott, D.W., Slack, G.W., Steidl, C., Mottok, A., Gascoyne, R.D., Connors, J.M., Sehn, L.H., Savage, K.J., Gerrie, A.S., Villa, D.

“…Patients with mantle cell lymphoma (MCL) follow a heterogeneous clinical course. While they generally require treatment initiation shortly after diagnosis, it…”
Get full text

Long‐term follow‐up of bulky classic Hodgkin lymphoma managed with ABVD and PET‐guided RT demonstrates excellent outcomes in PET‐negative cases by Kim, J. L., Villa, D., Tonseth, R. P., Gerrie, A. S., Wilson, D., Benard, F., Venner, C. P., Skinnider, B., Farinha, P., Slack, G. W., Lo, A. C., Scott, D. W., Sehn, L. H., Savage, K. J.

“…Summary The outcome of 221 patients with bulky (≥10 cm) classic Hodgkin lymphoma (cHL) treated with doxorubicin, bleomycin, vinblastine, dacarbazine and…”
Get full text

Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma by Gerrie, A.S., Power, M.M., Shepherd, J.D., Savage, K.J., Sehn, L.H., Connors, J.M.

“…High-dose therapy and autologous stem-cell transplant (HDT/ASCT) is the preferred treatment of chemosensitive relapsed/refractory Hodgkin lymphoma (HL). The…”
Get full text

CCTG LY18‐A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma ‐ the RGDP‐Venetoclax substudy by Assouline, S., Villa, D., Hay, A., Johnson, N., Crump, M., Kridel, R., Prica, A., Shamy, A., Gerrie, A., Savage, K., Kelly, J., Shepherd, L., Chen, B., Kuruvilla, J., Manji, F.

Get full text

Impact of the Dark Zone Signature on Central Nervous System Relapse in a Real‐World Diffuse Large B‐cell Lymphoma Population by Alduaij, W., Jiang, A., Collinge, B., Ben‐Neriah, S., Hilton, L. K., Boyle, M., Meissner, B., Farinha, P., Slack, G., Villa, D., Gerrie, A. S., Mungall, A. J., Steidl, C., Sehn, L. H., Scott, D. W., Savage, K.

Get full text

Multicohort Study of Conditional Survival and Cause of Death After Achieving Event‐Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL) by Wang, Y., Larson, M. C., Ekberg, S., Smedby, K. E., Zhao, E. J., Gerrie, A. S., Farooq, U., Maurer, M. J., Paludo, J., Nowakowski, G. S., Habermann, T. M., Albertsson‐Lindblad, A., Glimelius, I., Link, B. K., Diego, V., Jerkeman, M., Cerhan, J. R.

Get full text

RITUXIMAB IN COMBINATION WITH BENDAMUSTINE OR HIGH‐DOSE CYTARABINE‐BASED INDUCTION THERAPY IN TRANSPLANT‐ELIGIBLE PATIENTS WITH MANTLE CELL LYMPHOMA by Villa, D., Hoster, E., Hermine, O., Klapper, W., Szymczyk, M., Bosly, A., Unterhalt, M., Freeman, C. L., Scott, D. W., Gerrie, A. S., Savage, K. J., Sehn, L. H., Dreyling, M.

Get full text

OUTCOMES AFTER INITIAL REFUSAL OF CURATIVE TREATMENT IN PATIENTS WITH HODGKIN LYMPHOMA IN BRITISH COLUMBIA by Chahal, M., Jiang, A., Hayden, A., Savage, K., Villa, D., Scott, D., Gerrie, A., Lo, A., Chan, M., Pickles, T., Connors, J., Sehn, L., Freeman, C.

Get full text

TIME TO SECOND LINE BRUTON TYROSINE KINASE THERAPY AND AGE AT ITS INITIATION ARE STRONGLY ASSOCIATED WITH SUBSEQUENT OVERALL SURVIVAL IN PATIENTS WITH FIRST RELAPSE OF MANTLE CELL LYMPHOMA by Villa, D., Jiang, A., Crosbie, N., Rule, S., McCulloch, R., Visco, C., Buege, M. J., Kumar, A., Bond, D., Paludo, J., Maurer, M. J., Thanarajasingam, G., Baech, J., El‐Galaly, T., Kugathasan, L., Gerrie, A. S., Lewis, D.

Get full text

Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia by Owen, C, Gerrie, A S, Banerji, V, Assouline, S, Chen, C, Robinson, K S, Lye, E, Fraser, G

“…Chronic lymphocytic leukemia (cll) is the most common adult leukemia in North America. In Canada, no unified national guideline exists for the front-line…”
Get full text

SURVIVAL FOLLOWING FIRST RELAPSE IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA by Karmali, R., Donovan, A., Wagner‐Johntson, N., Messmer, M., Mehta, A., Anderson, J. K., Reddy, N., Kovach, A. E., Landsburg, D. J., Glenn, M., Inwards, D. J., Ristow, K., Lansigan, F., Kaplan, J. B., Caimi, P. B., Rajguru, S., Evens, A., Klein, A., Umyarova, E., Amengual, J. E., Lue, J. K., Diefenbach, C., Epperla, N., Barta, S. K., Hernandez‐Ilizaliturri, F. J, Handorf, E., Villa, D., Gerrie, A. S., Li, S., Mederios, J., Wang, M., Cohen, J., Calzada, O., Churnetski, M., Hill, B., Sawalha, Y., Gerson, J. N., Kothari, S., Vose, J. M., Bast, M., Fenske, T. S., Narayana Rao Gari, S., Maddocks, K. J., Bond, D., Bachanova, V., Kolla, B., Chavez, J., Shah, B.

Get full text

OUTCOME OF PATIENTS WITH RELAPSED AND REFRACTORY PERIPHERAL T CELL LYMPHOMA INTENDED FOR STEM CELL TRANSPLANT by Parkin, S., Wong, S., Connors, J.M., Sehn, L., Villa, D., Gerrie, A., Broady, R., Power, M., Toze, C., Song, K., Savage, K.J.

Get full text

WHOLE GENOME SEQUENCING OF MATCHED PRIMARY AND RELAPSED DLBCL REVEALS DISTINCT EVOLUTIONARY DYNAMICS ASSOCIATED WITH RELAPSE TIMING by Hilton, L. K, Collinge, B, Rushton, C. K, Ben‐Neriah, S, Dreval, K, Grande, B. M, Boyle, M, Meissner, B, Slack, G. W, Farinha, P, Craig, J. W, Gerrie, A. S., Freeman, C, Villa, D, Savage, K. J, Sehn, L. H, Marra, M. A, Steidl, C, Morin, R. D, Scott, D. W

Get full text

Marrow transplantation for severe aplastic anemia with significant renal impairment by Gerrie, A, Marsh, J, Lipton, J H, Messner, H, Gupta, V

Get full text

The Impact of Surveillance Imaging After Curative Intent Radiotherapy for Limited Stage Follicular Lymphoma by Urban, R., Chow, R., Pickles, T., Chan, M., Livergant, J., Gerrie, A., Freeman, C., Sehn, L.H., Scott, D., Villa, D., Savage, K.J., Slack, G., Lo, A.C.

“…Approximately 50% of patients treated with curative intent radiotherapy for limited stage follicular lymphoma (FL) will have a lymphoma relapse. The ideal…”
Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Alduaij, W, Jiang, A, Collinge, B, Ben-Neriah, S, Hilton, L K, Boyle, M, Meissner, B, Farinha, P, Slack, G, Villa, D, Gerrie, A S, Mungall, A J, Steidl, C, Sehn, L H, Scott, D W, Savage, K

Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Assouline, S, Villa, D, Hay, A, Johnson, N, Crump, M, Kridel, R, Prica, A, Shamy, A, Gerrie, A, Savage, K, Kelly, J, Shepherd, L, Chen, B, Kuruvilla, J, Manji, F

Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Wang, Y, Larson, M C, Ekberg, S, Smedby, K E, Zhao, E J, Gerrie, A S, Farooq, U, Maurer, M J, Paludo, J, Nowakowski, G S, Habermann, T M, Albertsson-Lindblad, A, Glimelius, I, Link, B K, Diego, V, Jerkeman, M, Cerhan, J R

Get full text

Multicohort Study of Conditional Survival and Cause of Death After Achieving Event-Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL) by Wang, YC, Larson, M, Ekberg, S, Smedby, K, Zhao, E, Gerrie, A, Farooq, U, Maurer, M, Paludo, J, Nowakowski, G, Habermann, T, Albertsson-Lindblad, A, Glimelius, I, Link, B, Villa, D, Jerkeman, M, Cerhan, J

Get full text